Eli Lilly has presented early clinical data for its experimental GIP/GLP-1 receptor agonist, brenipatide, which demonstrates a favorable safety profile and supports once-weekly dosing for potential use in substance use, psychiatric, and immunological disorders. This is significant because it expands the therapeutic potential of incretin-based therapies beyond diabetes and obesity, targeting conditions with substantial unmet needs. Lilly is now advancing brenipatide directly into Phase III trials for major depressive disorder and alcohol use disorder, a strategy driven by the large patient populations in these areas.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
